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OBJECTIVE—Multiple type 1 diabetes susceptibility genes
have now been identiﬁed in both humans and mice, yet mecha-
nistic understanding of how they impact disease pathogenesis is
still minimal. We have sought to dissect the cellular basis for how
the highly protective mouse Idd9 region limits the expansion of
autoreactive CD8
 T-cells, a key cell type in destruction of the
islets.
RESEARCH DESIGN AND METHODS—We assess the endog-
enous CD8
 T-cell repertoire for reactivity to the islet antigen
glucose-6-phosphatase–related protein (IGRP). Through the use
of adoptively transferred T-cells, bone marrow chimeras, and
reconstituted severe combined immunodeﬁcient mice, we iden-
tify the protective cell types involved.
RESULTS—IGRP-speciﬁc CD8
 T-cells are present at low fre-
quency in the insulitic lesions of Idd9 mice and could not be
recalled in the periphery by viral expansion. We show that Idd9
genes act extrinsically to the CD8
 T-cell to prevent the massive
expansion of pathogenic effectors near the time of disease onset
that occurs in NOD mice. The subregions Idd9.2 and Idd9.3
mediated this effect. Interestingly, the Idd9.1 region, which
provides signiﬁcant protection from disease, did not prevent the
expansion of autoreactive CD8
 T-cells. Expression of Idd9
genes was required by both CD4
 T-cells and a nonlymphoid cell
to induce optimal tolerance.
CONCLUSIONS—Idd9 protective alleles are associated with
reduced expansion of IGRP-speciﬁc CD8
 T-cells. Intrinsic ex-
pression of protective Idd9 alleles in CD4
 T-cells and nonlym-
phoid cells is required to achieve an optimal level of tolerance.
Protective alleles in the Idd9.2 congenic subregion are required
for the maximal reduction of islet-speciﬁc CD8
 T-cells.
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T
he nonobese diabetic (NOD) mouse model of
type 1 diabetes has proven to be extremely
valuable in the study of this chronic disease.
Tolerance of both the CD8
 and CD4
 T-cell
subsets toward islet -cells is perturbed in the NOD mouse
resulting in -cell destruction. This loss of tolerance is
determined by the more than 18 genetic regions, termed
Idd regions, identiﬁed as contributing to diabetes suscep-
tibility (1). The multiplicity of genes contributing to dis-
ease progression in both mice and humans most likely
reﬂects several checkpoints of tolerance that must be
bypassed for overt disease to occur.
Expression of the protective B10 alleles of Idd9 in
NOD.B10 Idd9 congenic mice (Idd9 mice) reduces the
incidence of diabetes from 80% in the NOD parental
strain to 4% in Idd9 mice (2). Interestingly, Idd9 mice
still develop extensive insulitis and produce islet-speciﬁc
autoantibodies, indicating that islet-speciﬁc tolerance is
not complete and that a late checkpoint of tolerance may
be functioning to constrain the autoimmune response (3).
The Idd9 region on chromosome 4 is composed of at least
three separate intervals, Idd9.1, Idd9.2, and Idd9.3 (2).
Fine-mapping, functional, and sequence data from the
Idd9.3 region suggest that the gene encoding CD137
(4–1BB) is the most likely candidate gene for Idd9.3 (2,4).
Several studies have examined the contribution of Idd9
genes to disease protection. We have recently shown that
CD8
 T-cell tolerance to transgenic hemagglutinin ex-
pressed under the rat insulin promoter (InsHA) is restored
in Idd9-InsHA mice (5). Unlike mice expressing protective
Idd3 and Idd5 alleles, tolerance was not restored upon
initial activation of autoreactive CD8
 T-cells in the pan-
creatic draining lymph nodes (PcLNs) but at an unknown
later time. When Idd9 genes were expressed by T-cells
from BDC2.5 transgenic mice, the ability of these cells to
transfer diabetes into NOD–severe combined immunode-
ﬁcient (SCID) recipients was reduced (6). Idd9.1 was
recently reported to control the suppressive activity of
regulatory CD4
 T-cells (7). Idd9 may also contribute to
protection of islet -cells from cytotoxic T-lymphocyte
(CTL) killing (8). Idd9/11 (a B6-derived region overlapping
Idd9.1 and Idd9.2) was also reported to diminish the
diabetogenic potential of CD4
 T-cells (9), as well as
normalizing tolerance of pathogenic B-cells (10). In the
present study, restored CD8
 T-cell tolerance to the
islet-expressed antigen, islet-speciﬁc glucose-6-phospha-
tase–related protein (IGRP), by Idd9 genes was assessed.
We have focused on the identiﬁcation of the cell types that
must express Idd9 genes and on the Idd9 subregions
responsible for CD8
 T-cell tolerance.
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Mice. Experimental procedures were performed according to the National
Institutes of Health Guide for the Care and Use of Laboratory Animals
(protocol number 09–0074). Clone-4 T-cell receptor (TCR) NOD mice and
NOD-CD45.2 congenic mice were previously described (5,11). Thy1.1
NOD-
8.3-SCID mice were generated by intercrossing NOD-8.3 TCR transgenic mice
(The Jackson Laboratory), with NOD-SCID mice (Taconic) and NOD-Thy1.1
mice (5). NOD-MrkTac mice (Taconic) and B10.D2 mice (The Scripps Re-
search Institute breeding colony) were purchased. The NOD.B10 Idd9 con-
genic strain (Taconic line 905), which contains a continuous B10-derived DNA
segment including type 1 diabetes–protective alleles Idd9.1, Idd9.2, and
Idd9.3 (Fig. 1), has been previously described (5). The gene content of the
congenic intervals present in NOD-Idd9.1 (line 1565) and NOD-Idd9.3 (line
1106) mice has been described previously (4,7), and NOD-Idd9.2 (line 1566) is
depicted in Fig. 1. Idd9 (line 905) mice were intercrossed with NOD-SCID
/
mice to generate Idd9-SCID
/ mice, and NOD-Thy1.1
 mice to generate
Idd9-Thy1.1
 mice.
Virus. Recombinant vaccinia virus expressing the H-2K
d–restricted epitope
VYLKTNVFL, amino acid residues 206–214 of murine IGRP (Vac-IGRP), was
generated as described (12). Vac-K
dHA has been previously described (5).
Mice were infected intraperitoneally with 1  10
7 plaque-forming units (pfu)
of virus and CD8
 T-cell responses measured in the spleen 7 days later.
Preparation and adoptive transfer of T cells. TCR transgenic 8.3 or
Clone-4 CD8
 T-cells were isolated from the spleen and lymph nodes of TCR
transgenic mice (6–8 weeks of age) using a CD8
 T-cell enrichment kit (BD
Biosciences). Recipient female mice (6–10 weeks) were injected intrave-
nously with 1  10
4 puriﬁed 8.3 or Clone-4 cells mixed with 2  10
6 total NOD
or Idd9 spleen cells (syngeneic with the recipient mouse) as carrier cells.
SCID mice were reconstituted with spleen and lymph node cell populations
derived from 3-to 4-week-old donor mice. Total CD8
 T-cells and CD4
 T-cells
were puriﬁed with a CD8
 T-enrichment kit and CD4
 T-enrichment kit (BD
Biosciences) using double the recommended amount of reagents. In some
experiments, the CD4
 T-cells were further puriﬁed by sorting for CD4

Thy1.2
 cells with a FACSAria (BD Biosciences). CD4
 T-cells and CD8

T-cells were depleted with CD4
 microbeads and CD8
 microbeads (Miltenyi)
using double the recommended amount of beads.
In vivo CTLs. Mice were injected intravenously with 1  10
7 of a 50:50 mix-
ture of carboxyﬂuorescein succinimidyl ester
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11 5
125
135
145
155
Idd9.1
Idd9.2
Idd9.3
= B10 region
= NOD region
= region betwen in and out marker
120
130
140
150
Mb Markers
D4mit200
D4mit258
CD30_Distal-5
Pik3cd-RE
Calstnl-RE
D4mit339
rs27543340
D4mit42
D4mit127
D4mit59
AL606963(TA)
AL606914(TGCA)
905 1565 1106 1566
NOD.B10
Idd9.1,2,3
NOD.B10
Idd9.1
NOD.B10
Idd9.2
NOD.B10
Idd9.3
145
145.5
146
146.5
147
147.5
148
148.5
149
144.75
145.25
145.75
146.25
146.75
147.25
147.75
148.25
148.75
149.25
AL606963(TA)
CD30-Distal-5
Calstn1-RE
Pik3cd-RE
CD30 (TNFRSF1b)
Tnfr2 (TNFRSF8)
Plod1
Nppb Nppa Clcn6
Mthfr AL606929.13-2 Agtrap
Mad2l2
Fbxo6b
Frap
Masp2 T ardbp
Dffa Cort Apitd1
Ube4b
Rbp7
Nmnat1 Lzic
Ctnnbip1Clstn1
Pik3cd Tmem201
MOUSE
Mb
1700029101Rik
RP23-384D6.6
1700029101Rik
RP23-282n17.7
RP23-285n14.1
RP23-284n14.6
AL929465.6-2
CU062436.5
RP23-383l4.2
RP23-383l4.3
2810408p10Rik
2510039018Rik
2610109H07Rik
Mfn2 FV1 D4wsu114e
Fbxo44 Fbxo2
Ptchd2 Al645605.14
Angptl7
Ubiad1
Exosc10
Casz1
Srm
Pex14
Pgd Kif1b
Line 1566 Chromosome 4
Idd9.2
Idd9.2
=3.923 Mb
RP23-331p21.6
= defines Idd interval based on fine-mapping in 
Pere, et al. (7) for Idd9.1, (this paper) for Idd9.2 and 
Cannons, et al. (4) for Idd9.3. 
1700021l01Rik
Rex2
AL606931.6-1
AL606931.6-2
RP23-362E2.2
RP23-362E2.4
AL626778.12-2
2610305D13Rik
RP23-282E3.3
1700021l01Rik
= gap within the B6 sequence
FIG. 1. Map of the Idd9 congenic intervals contained in lines 905, 1565, 1566, and 1106 and the gene content of Idd9.2. Gaps in the assembly of
the B6 sequence are marked.
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low control NOD splenocytes as described
(13).
Flow cytometry. Isolation of islet lymphocytes was performed as previously
described (5). CD8
 T-cells were stained with H-2K
d–IGRP206–214–phyco-
erythrin (PE) tetramers (National Institute of Allergy and Infectious Diseases
MHC Tetramer core facility) for 15 min at room temperature, followed by
staining with anti–CD8–ﬂuorescein isothiocyanate (FITC) at 4°C for 15 min.
Cells were acquired with either a FACSCalibur or LSRII (both from BD
Biosciences) and analyzed with FlowJo software.
Bone marrow chimeras. Bone marrow cells were prepared as previously
described (11). Brieﬂy, mice were irradiated (1,200 rad) and reconstituted
with 7–8  10
6 bone marrow cells that had been depleted of Thy1
 cells by
complement-mediated lysis. Mice were further depleted of residual T-cells
with anti-CD4 and anti-CD8 depleting antibodies.
Statistical analysis. Differences between groups were tested via the Mann-
Whitney test and median values are reported in the text unless otherwise
noted, with ﬁrst to third interquartile ranges (IQRs). Mean values are reported
as mean  SD.
RESULTS
Idd9 congenic mice have reduced numbers of IGRP-
speciﬁc CD8
 T-cells. To assess whether tolerance to
the endogenous islet antigen IGRP was restored in Idd9
mice (line 905, Fig. 1), we infected NOD and Idd9 female
mice with a vaccinia virus encoding the H-2K
d-IGRP206–214
epitope (Vac-IGRP) (Fig. 2A and B). The frequency of
IGRP-speciﬁc CD8
 T-cells in Idd9 mice (0.5%) was sig-
niﬁcantly reduced compared with NOD (5.2%) and was
similar to that found in B10.D2 control mice (0.4%),
indicating that IGRP-speciﬁc CD8
 T-cells had been elim-
inated or were unresponsive in Idd9 and B10.D2 mice (Fig.
2A). The total number of IGRP-speciﬁc CD8
 T-cells was
also signiﬁcantly reduced in Idd9 and B10.D2 mice com-
pared with NOD (Fig. 2B). We demonstrated previously
that both NOD and Idd9 mice develop robust responses to
a non–self-antigen (HA) after infection with Vac-K
dHA (5).
Furthermore, transferred naive HA-speciﬁc Clone-4 cells
expand with equal efficiency in NOD and Idd9 mice after
infection with Vac-K
dHA (supplementary Fig. 1, available
in an online appendix at http://diabetes.diabetesjournals.
org/content/early/2010/03/10/db09-1801/suppl/DC1). Thus,
the reduction in IGRP-speciﬁc CD8
 T-cell responses does
not signify a comprehensive difference in the viral re-
sponse between the strains, but rather an antigen-speciﬁc
response.
FIG. 2. The frequency of IGRP-speciﬁc CD8
 T-cells is signiﬁcantly reduced in Idd9 congenic mice. NOD, NOD-Idd9, and B10.D2 10- to
14-week-old female mice were infected with 1  10
7 pfu Vac-IGRP i.p. On day 7 after infection, spleens were analyzed by ﬂuorescence-activated
cell sorter (FACS) for CD8
 IGRP-tetramer
 cells. Pooled results from three experiments are shown; horizontal lines show median value. A:
Frequency P < 0.0001 (***) of NOD (5.2%, IQR: 2.4–9.4%) vs. Idd9 (0.5%, IQR 0.4–0.6%) using the Mann-Whitney test. B: Total cell number P <
0.0001 (***) of NOD (1,731  10
3, IQR 996–2,939) vs. Idd9 (133  10
3, IQR 103–205) using the Mann-Whitney test. C and D: Islet-inﬁltrating
leukocytes were isolated from the pancreas of NOD and Idd9 10- to 14-week-old female mice (three pooled mice). Pancreas leukocytes and PcLN
cells were stained with IGRP-H2K
d tetramer anti-CD8
 and propidium iodide. C: Individual FACS plots. D: Collective data from three
experiments. Line depicts mean value. PcLN, NOD (0.15  0.04%) vs. Idd9 (0.08  0.03%), P  0.06; pancreas, NOD (4.8  2.1%) vs. Idd9 (0.4 
0.4%), P  0.0015 (**, mean  SD, P value calculated using unpaired t test). NS, not signiﬁcant.
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T-cells was also detectable in the islets prior to expansion
of the IGRP-speciﬁc population with virus (Fig. 2C and D).
IGRP-speciﬁc CD8
 T-cells were found inﬁltrating the
islets of NOD but not Idd9 mice (4.8% vs. 0.4% of CD8

cells, respectively, P  0.0015). A small reduction in the
frequency of tetramer
 cells was also observed in the
PcLN of Idd9 (0.08%) compared with NOD mice (0.15%,
Fig. 2B); however, the frequencies were extremely low in
the PcLN and this difference did not reach signiﬁcance
(P  0.06). One previous study reported a reduction in the
frequency of CD8
 T-cells in the islet inﬁltrates of Idd9
mice (8); however, we did not observe this difference
(supplementary Fig. 2). We conclude that NOD and Idd9
mice have a profoundly altered CD8
 T-cell functional
repertoire to IGRP, observable both with and without
prior expansion by Vac-IGRP infection.
Idd9.2 and Idd9.3 region genes contribute to re-
stored CD8
 T-cell tolerance. The Idd9 region has been
reported to contain at least three separate subregions
(Idd9.1, Idd9.2, and Idd9.3, Fig. 1). Congenic strains
having only one of the protective regions are each partially
protected from diabetes (2,4,7). To determine which of
these regions contributes to restored tolerance to islet
IGRP, subcongenic mice were infected with Vac-IGRP and
the frequency of IGRP-speciﬁc tetramer
 cells was as-
sessed (Fig. 3A). As expected from the results in Fig. 2A,
Idd9 mice were highly tolerant compared with NOD mice.
Idd9.1 mice contained very high percentages of IGRP-
speciﬁc cells (7.9%). Idd9.2 mice exhibited a greatly
reduced frequency of IGRP-speciﬁc cells (0.8%) that was
similar to Idd9 mice (1.1%). Idd9.3 mice showed an
intermediate frequency (2.0%). Therefore, at least two
genes within the Idd9 region contribute to tolerance of
IGRP-speciﬁc CD8
 T-cells and these are within the Idd9.2
and Idd9.3 regions.
We also assessed the effector function of the IGRP-
speciﬁc CD8
 T-cells that expanded after infection with
Vac-IGRP by measuring in vivo CTL activity (Fig. 3B).
NOD mice had a very high efﬁciency of IGRP-speciﬁc
killing (85%), whereas Idd9 mice had low levels of killing
(27%). Idd9.2 mice were intermediate between NOD and
Idd9 (36%), but neither Idd9.1 (82%) nor Idd9.3 (83%)
showed any reduction. We interpreted this to mean that
mice with an intermediate frequency of IGRP-speciﬁc
tetramer
 CD8
 T-cells (such as Idd9.3) had sufﬁcient
numbers of CTLs to efﬁciently kill the available in vivo
targets. These data further verify that among the three
Idd9 regions, Idd9.2 has the greatest capacity to protect
from the expansion of pathogenic islet-speciﬁc CTLs.
Idd9 genes expressed in the host prevent the late
expansion of autoreactive CD8
 T-cells in the pe-
riphery. Successful peripheral tolerance of autoreactive
CD8
 T-cells in Idd9 mice could be due to expression of
tolerance-inducing Idd9 genes either by the CD8
 T-cell or
by other cells, or both. We used TCR transgenic NOD-8.3
CD8
 T-cells, speciﬁc for IGRP206–214 to assess this issue
(14). NOD-Thy1.1
 8.3 cells (1  10
4) were transferred into
either NOD or Idd9 recipients, and 2, 5, 6.5, or 8 weeks
later the mice were infected with Vac-IGRP and the
frequency of Thy1.1
 8.3 cells was determined (Fig. 4). At
2 and 5 weeks, no signiﬁcant difference in the frequency of
8.3 cells was observed between NOD and Idd9 mice (Fig.
4A). However, 6.5 and 8 weeks later the 8.3 T-cells
expanded in the NOD mice (mean 4.6  3.9% at 8 weeks)
but were not detected in Idd9 (mean 0.2  0.4% at 8 weeks,
Fig. 4A and B).
To verify that NOD CD8
 T-cells transferred into Idd9
mice were not deleted because of an allodifference emanat-
ing from the Idd9 congenic interval, we transferred NOD
HA-speciﬁc Thy1.1
 Clone-4 CD8
 T-cells (1  10
4) into
NOD and Idd9 mice. After 2, 5, 6.5, or 8 weeks, the remaining
Clone-4 cells were expanded with Vac-K
dHA. A similar pro-
portion of Clone-4 cells expanded in both NOD and Idd9
mice at all time points (supplementary Fig. 1), indicating that
NOD CD8
 T-cells are not rejected in Idd9 mice.
Intrinsic expression of protective Idd9 alleles in
CD8
 T-cells does not establish CD8
 T-cell toler-
ance. The fact that NOD-8.3 CD8
 T-cells were tolerized
in Idd9 hosts suggested that tolerance was caused by
NOD
Idd9
Idd9.1
Idd9.2
Idd9.3
0.125
0.25
0.5
1
2
4
8
16
32
***
***
* A
I
G
R
P
-
s
p
e
c
i
f
i
c
 
c
e
l
l
s
 
(
%
 
o
f
 
C
D
8
)
I
G
R
P
 
s
p
e
c
i
f
i
c
 
k
i
l
l
i
n
g
 
(
%
)
NOD
Idd9
Idd9.1
Idd9.2
Idd9.3
B10.D2
0
25
50
75
100
B
***
*
FIG. 3. Idd9.2 and Idd9.3 genes contribute to restored tolerance of
IGRP-speciﬁc CD8
 T-cells. NOD, Idd9, Idd9.1, Idd9.2, and Idd9.3 mice
(10–14 weeks of age) were infected with Vac-IGRP and 7 days later (A)
IGRP-tetramer
 CD8
 T-cells were measured in the spleen. Pooled
data from three experiments are shown. The median line is shown for
each group. NOD (3.5%, IQR 1.9–7.0%) vs. Idd9.2 (0.8%, IQR 0.4–
1.7%), P < 0.0001 (***); and NOD vs. Idd9.3 (2.0%, IQR 0.9–3.0%), P 
0.047 (*), using the Mann-Whitney test. B: Infected and naive control
mice were injected with CFSE
High IGRP206–214–loaded NOD (or B10.D2)
splenocytes and CFSE
low control NOD (or B10.D2) splenocytes. Killing
was assessed 16 h later in the spleen by FACS. Speciﬁc killing was
calculated by the formula: 100  [(percentage of CFSE
high/percentage
of CFSE
low)/Ratio naive)  100]. Pooled data from three experiments
are shown. Line depicts median value. NOD (85%, IQR 43–94%) vs.
Idd9 (27%, IQR 16–43%), P  0.0004 (***); NOD vs. Idd9.2 (36%, IQR
18–88%), P  0.027 (*).
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that intrinsic expression of Idd9 genes by CD8
 T-cells
contributed to tolerance. To test this possibility, CD8

T-cells from 3-week-old Idd9-Thy1.1
 mice (4  10
6) were
puriﬁed and adoptively transferred into NOD-SCID hosts
together with CD8
-depleted (90% reduction) NOD-
Thy1.2
 splenocytes (30  10
6), from 3-week-old mice.
Splenocytes from 3-week-old NOD and Idd9 mice con-
tained only background frequencies of IGRP-speciﬁc
CD8
 T-cells as assessed by tetramer staining. A second
group of mice was prepared similarly but with CD8

T-cells from NOD-Thy1.1
 donors. After 10 weeks, the
mice were infected with Vac-IGRP and the presence of
IGRP-tetramer binding CD8
 T-cells determined (Fig. 5A
and B). In both groups of mice, approximately half of the
CD8
 T-cells were Thy1.1
 at the conclusion of the
experiment (supplementary Fig. 3A). We also conﬁrmed
that the majority of the CD4
 T-cell population was of
NOD-Thy1.2
 origin (supplementary Fig. 3B). Thus, Idd9-
derived cells contributed signiﬁcantly only to the CD8

T-cell population and not to other cell types. When Idd9-
Thy1.1
 CD8
 T-cells were mixed with NOD-Thy1.2

spleen and lymph node cells, a high frequency of IGRP-
speciﬁc CD8
 T-cells expanded (Fig. 5A). In both groups,
the IGRP-speciﬁc cells were derived from both the
Thy1.1
 and Thy1.2
 populations, as shown in Fig. 5B.
Although individual mice differed in whether the IGRP

cells were predominantly derived from the Thy1.1
 or
Thy1.2
 population, the overall frequency of IGRP-speciﬁc
cells was comparable between the groups (Fig. 5A). Thus,
the peripheral repertoire of 3-week-old Idd9 mice contains
autoreactive IGRP-speciﬁc CD8
 T-cells that are able to
expand and survive when transferred into mice that ex-
press susceptible NOD alleles on all other cell types. These
results directly demonstrate that intrinsic expression of
Idd9 genes within the CD8
 T-cells does not prevent their
expansion in a NOD host.
Idd9 bone marrow–derived cells are sufﬁcient to
maintain CD8
 T-cell tolerance in a NOD host.
Radiation chimeras were produced to determine which
host cell types must express Idd9 genes for maintenance
of tolerance. Thy1.2
 Idd9 or NOD recipients were irradi-
ated and reconstituted with Thy1.1
 Idd9 or NOD bone
marrow cells and rested for 12 weeks. Reconstitution with
Thy1.1
 donor T-cells varied between 71 and 88%, with no
difference observed in reconstitution by NOD versus Idd9
bone marrow (supplementary Fig. 4). After infection with
Vac-IGRP, the frequency of tetramer
 cells in the
NOD3NOD chimeras was signiﬁcantly higher than that
found in the Idd93Idd9 chimeras (2.9 vs. 0.5%, Fig. 6A).
When Idd9 bone marrow was used to reconstitute NOD
hosts, IGRP-speciﬁc tolerance was well maintained com-
pared with NOD3NOD (0.5%, Fig. 6A). Thus, an Idd9
hematopoietic cell is able to restore CD8
 T-cell tolerance
in an NOD host. NOD3Idd9 chimeric mice (0.9%) had
signiﬁcantly fewer IGRP-speciﬁc cells than NOD3NOD,
yet signiﬁcantly more than Idd93Idd9 (Fig. 6A). This may
be due to tolerance by expression of Idd9 genes within a
host parenchymal cell, or the 20% residual Idd9 hemato-
poietic cells may have a sufﬁciently strong dominant effect
to afford some tolerance, or both.
To determine whether Idd9 hematopoietic cells were
dominant for tolerance, chimeras were made as described
above, but a 50:50 mixture of NOD:Idd9 (or NOD-Thy1.1
:
Idd9) bone marrow was used to reconstitute NOD or Idd9
irradiated hosts (Fig. 6B). The mixed chimeras in both
hosts maintained IGRP-speciﬁc CD8
 T-cell tolerance well
and were not signiﬁcantly different from each other or
Idd93Idd9 control chimeras. We concluded that the
mechanism of tolerance established by Idd9 hematopoi-
etic cells is dominant as it overrides the presence of cells
expressing NOD genes in the same animal.
Expression of protective Idd9 alleles by a nonlym-
phocyte population contributes to restoration of
CD8
 T-cell tolerance. To learn more about the cell
types responsible for tolerance induction, Idd9-SCID or
NOD-SCID mice were reconstituted with total spleen and
lymph node cells isolated from 3- to 4-week-old NOD or
Idd9 donor mice. After 10 weeks of reconstitution, we
infected the mice with Vac-IGRP and assessed the spleen
for IGRP-tetramer
 cells (Fig. 6C). NOD3NOD-SCID re-
constituted mice had many IGRP-speciﬁc CD8
 T-cells
(12.9%), signiﬁcantly more than NOD3Idd9-SCID recon-
stituted mice (1.5%). Idd93Idd9-SCID reconstituted mice
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FIG. 4. Deletion of NOD-8.3 CD8
 T-cells is restored in Idd9 mice. NOD-Thy1.1
 8.3 T-cells (1  10
4) were transferred into 7- to 10-week-old NOD
or Idd9 mice. A: After 2, 5, 6.5 or 8 weeks, mice were infected with Vac-IGRP, and the frequency of Thy1.1
 CD8
 T-cells was determined in the
spleen 7 days later. Data from between 3 and 14 mice are pooled per time point. Mean  SEM is shown. ND, not done. B: Individual mice from
the 8-week time point are shown. NOD vs. Idd9 at 8 weeks, P < 0.0001 (***) using the Mann-Whitney test. The mean line is shown for each group.
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 cells (0.8%, Fig. 6C). This
frequency was signiﬁcantly increased in Idd93NOD-SCID
reconstituted mice (1.5%). A comparison of NOD-SCID
mice reconstituted with NOD or Idd9 spleen and lymph
node cells revealed that this population contains at least
one cell type contributing to tolerance (P  0.01). Like-
wise, Idd9-SCID mice reconstituted with NOD cells were
less tolerant than when reconstituted with Idd9 cells (P 
0.04). Thus, expression of susceptible NOD alleles in both
the donor cells and a nonlymphocyte host cell (either a
parenchymal cell or a nonlymphocyte hematopoietic cell,
e.g., an antigen-presenting cell) inhibits tolerance induc-
tion by protective Idd9 alleles.
Expression of protective Idd9 alleles in CD4
 T-cells
contributes to restoration of CD8
 T-cell tolerance.
A likely candidate for an Idd9-expressing lymphoid cell
that restores tolerance in SCID recipients is the CD4

T-cell. To test this directly, we reconstituted NOD-SCID
mice with highly puriﬁed CD4
 T-cells from 4-week-old
NOD or Idd9 mice cotransferred with CD4-depleted NOD
spleen and lymph node cells expressing a congenic allo-
marker (either Thy1.1 or CD45.2). At 10 weeks after
reconstitution, the CD4
 T-cell population comprised a
mean of 70  25% of cells derived from the puriﬁed NOD
or Idd9 CD4
 noncongenic population (supplementary
Fig. 5A). The CD8
 T-cell population, however, was pri-
marily derived from the NOD congenic splenocyte popu-
lation (supplementary Fig. 5B). Thus, Idd9-derived cells
contributed signiﬁcantly to the CD4
 T-cell population but
not to other cell types. The mice were infected with
Vac-IGRP and IGRP-speciﬁc CD8
 T-cells assessed (Fig.
7). Control mice reconstituted with NOD CD4
 T-cells
mixed with CD4
-depleted NOD spleen and lymph node
cells developed high frequencies of IGRP-speciﬁc CD8

T-cells (5.6%, IQR: 2.7–13%). In contrast, Idd9 CD4
 T-cells
prevented the loss of CD8
 T-cell tolerance to islet IGRP
(1%, IQR: 0.7–2.1%). Tolerance occurred even in mice in
which only 50–60% of the CD4
 T-cells expressed protec-
tive alleles of Idd9 genes, which is consistent with the
dominant tolerance observed in the mixed chimeric mice
(Fig. 6B).
One way in which dominant tolerance may be imple-
mented is via regulatory T-cells that may be increased in
number or function. We did not observe any difference in
the frequency or number of regulatory T-cells between
Idd9 and NOD mice (supplementary Fig. 6). We did,
however, ﬁnd a notable change in the ratio of naive to
effector phenotype CD4
 T-cells between the two strains
(Fig. 8). NOD mice had fewer naive cells and increased
effector cells than Idd9 mice as assessed by staining for
CD62L and CD44.
DISCUSSION
Diabetes susceptibility genes may contribute to disease
pathogenesis through alterations of distinct phases of
disease such as thymic or peripheral deletion, expansion
of self-reactive cells and immune regulation, or effects on
apoptosis of the -cells (15). We hypothesized that many
key genes will regulate the expansion of pathogenic CD8

T-cells, the cell type ultimately responsible for the destruc-
tion of the islets. We previously reported that protective
alleles of several Idd regions act to restore CD8
 T-cell
tolerance to islet antigens in NOD mice (5,16). Here we
have further dissected the cell types through which Idd9-
protective alleles achieve CD8
 T-cell tolerance.
We chose to examine CD8
 T-cells speciﬁc for IGRP, as
these T-cells are found at high frequencies in islet inﬁl-
trates, and increased frequencies of these cells in the
peripheral blood are predictive of diabetes progression in
individual NOD mice (17). Although it is unlikely that
IGRP is the autoantigen that triggers disease (18), toler-
ance to this antigen serves as a general model for toler-
ance to islet proteins. Tolerance to a surrogate islet
antigen, transgenic HA, was also restored by Idd9 genes
(5); however, we cannot exclude that other islet-speciﬁc
CD8
 T-cells may exist that do not conform to this
principle. We found that the frequency of IGRP-speciﬁc
CD8
 T-cells was dramatically reduced in Idd9 mice
compared with NOD. Markedly few IGRP-speciﬁc cells
were found in the islets, despite the presence of other
CD8
 T-cells and lymphocyte inﬁltrates, suggesting Idd9
restores islet antigen–speciﬁc tolerance. We had previ-
ously shown that adoptively transferred naive NOD TCR
transgenic CD8
 T-cells became activated to an islet
antigen in the PcLNs and the highly proliferated cells
inﬁltrated the islets of Idd9 mice on day 4 after transfer
(5,16). The absence of endogenous islet-speciﬁc CD8

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FIG. 5. Intrinsic expression of Idd9 genes within the CD8
 T-cell does
not mediate CD8
 tolerance by Idd9 genes. Puriﬁed NOD or Idd9
Thy1.1
 CD8
 T-cells (4  10
6) from 3-week-old donor mice were
cotransferred with partially (90%) CD8
 T-cell–depleted Thy1.2
 NOD
spleen and LN cells (30  10
6) into NOD-SCID mice. After 10 weeks,
mice were infected with Vac-IGRP and IGRP-tetramer
 CD8
 T-cells
measured in the spleen 7 days later. A: Frequency of IGRP-speciﬁc cells
among all CD8
 T-cells; pooled data from two experiments are shown
and indicated by circles and triangles; horizontal lines depict mean
values. B: Thy1.1 and IGRP-speciﬁc tetramer staining of CD8
 T-cells;
one representative animal shown.
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tolerance after they enter the islets. CD8
 T-cells of other
speciﬁcities were found in the pancreatic inﬁltrates. These
cells may be speciﬁc for non–self-antigens, such as envi-
ronmental antigens, as we have observed in other models
(12).
Upon transfer of 8.3 CD8
 T-cells to NOD versus Idd9
recipients, we observed a dramatic difference in the num-
bers of cells recovered 6.5–8 weeks after transfer. Both
groups were similar at the early time points, consistent
with our previous observation that early activation of
transferred CD8
 T-cells occurs in both strains (5,16). The
time of expansion occurred when the mice were 13–15
weeks of age, which correlates with the ﬁrst age of onset
of diabetes in our colony. Thus, expansion of islet antigen–
speciﬁc CD8
 cells may accompany disease progression.
The observation that transferred NOD-8.3 T-cells were
tolerized in Idd9 mice demonstrates that Idd9 genes
expressed by cells in the host restore peripheral tolerance.
We have not yet been able to directly determine whether
8.3 cells transferred into Idd9 mice undergo tolerance
through anergy or deletion. Because of limitation in anti-
gen availability, it is necessary to transfer a very small
number of cells to ensure complete activation in the PcLN.
When larger cell numbers are used, a population of naive
cells remains in the mice for many weeks (19). The fact
that a strong stimulus such as Vac-IGRP does not promote
activation suggests deletion rather than anergy may occur.
It is also possible that Idd9 genes contribute to correct-
ing the defective thymic tolerance described in NOD mice
(20,21). We did not see any evidence that thymic tolerance
signiﬁcantly contributed to IGRP-speciﬁc CD8
 tolerance.
Mature CD8
 T-cells isolated from the periphery of both
Idd9 and NOD mice contained IGRP-speciﬁc CD8
 T-cells
that expanded and accumulated when transferred into an
NOD environment, also indicating that endogenous ex-
pression of Idd9 genes did not promote tolerance. Thus,
the Idd9 thymus failed to remove self-reactive IGRP-
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FIG. 6. Expression of Idd9 genes by both hematopoietic cells and
nonlymphocytes contributes to CD8
 T-cell tolerance. Recipient
female Thy1.2
 mice were irradiated with 1200 rad and reconstituted
with 7  10
6 T-cell–depleted bone marrow cells from Thy1.1
 donors
(A) or a 50:50 mix of NOD and Idd9 bone marrow (B). After 12
weeks, the mice were infected with 1  10
7 pfu Vac-IGRP. Spleno-
cytes were stained 7 days later with anti-CD8-FITC and IGRP-
tetramer-PE. Pooled data from three experiments are shown.
Horizontal line depicts median value. A: NOD3NOD vs. Idd93NOD
P  0.0006 (***), NOD3NOD vs. NOD3Idd9 P  0.006 (**),
Idd93NOD vs. Idd93Idd9 P  0.24, NOD3Idd9 vs. Idd93Idd9 P 
0.004 (**), NOD3NOD vs. Idd93Idd9 P < 0.0001 (Mann-Whitney
test). B: NOD3NOD vs. mix3NOD P  0.005 (**), NOD3NOD vs.
Idd93Idd9 P  0.016 (Mann-Whitney test). C: NOD-SCID and
Idd9-SCID mice were reconstituted with 2  10
7 spleen and LN cells
from 3- to 4-week-old NOD or Idd9 mice. After 10 weeks, the mice
were infected with Vac-IGRP, and IGRP-tetramer
 CD8
 T-cells were
measured in the spleen 7 days later. Pooled data from three experi-
ments are shown.
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low expression of IGRP in the thymus (18), and would not
necessarily be the case for all islet antigens or all islet
reactive T cells.
Experiments in which puriﬁed Idd9 CD4
 cells were
found to transfer tolerance into a NOD-SCID host strongly
support a role for CD4
 T-cells in disease protection. It is
likely that Idd9 genes act intrinsically to the CD4
 T-cell,
although it is also possible that expression in another cell
type during development permanently altered the Idd9
CD4
 T-cell compartment rendering them tolerogenic. As
the cells were transferred 10 weeks before CD8
 T-cell
tolerance was assessed in the reconstituted hosts, this
seems unlikely. Although we have observed a dominant
protection by Idd9 bone marrow, we have not observed
evidence of altered frequencies of CD4
 regulatory T-cells
in Idd9 mice. We did, however, ﬁnd a notable change in the
ratio of naive to effector phenotype CD4
 T-cells between
the two strains: NOD mice had fewer naive cells and
increased effector cells. Thus, the presence of NOD sus-
ceptible alleles of Idd9 genes appears to support higher
numbers of activated CD4
 T-cells, which may then pro-
vide increased “help” to CD8
 T-cells, e.g., by licensing of
dendritic cells (DCs) or within the target tissue (22,23).
This is the subject of ongoing research. It is also possible
that Idd9 regulatory T-cells have enhanced suppressive
ability, as suggested elsewhere (7).
Dissection of the Idd9 region into three subregions has
been previously described (2). We have found that Idd9.2
is the most potent region in regard to restraining the
expansion of autoreactive CD8
 T-cells, whereas Idd9.1
had no such effect. However, all three Idd9 regions have
similar diabetes frequencies (2,4,7). This implies that the
amount of expansion of autoreactive CD8
 T-cells does
not correlate directly with disease progression. Idd9.1 has
been described to increase the suppressive function of
regulatory T-cells (7). This may result in reduced diabetes
incidence without altering the frequency of IGRP-speciﬁc
CD8
 T-cells that expand upon viral infection. We con-
clude that CD8
 tolerance is an active mechanism strongly
modulated by Idd9.2 genes.
Fine-mapping of Idd9.2 is ongoing to deﬁne which genes
in the current interval are positional candidate genes. One
gene in the Idd9.2 region, Fbxo2, was recently reported to
have a twofold lower expression level in NOD than pro-
tected Idd9.2 mice (24). Idd9.3 is a small congenic interval
containing only 15 genes including the primary candidate
Cd137 (41bb) (4). CD137 is expressed on activated T-cells
as well as activated DCs where it has recently been
described to support DC survival after maturation (25).
Thus, is it plausible that Idd9.3 could function pleiotropi-
cally on both CD4
 T-cells and DCs. We are currently
working to identify the cell types in which Idd9.2 and
Idd9.3 must be expressed for optimal tolerance induction.
Through identiﬁcation of the protective pathways of genes
such as Idd9.2 and Idd9.3, it is possible that targets for
future type 1 diabetes therapies or preventative treatments
may be identiﬁed.
FIG. 7. CD4
 T-cells expressing Idd9 genes are sufﬁcient to restore
CD8
 tolerance in NOD mice. Puriﬁed NOD or Idd9 Thy1.2/CD45.1
CD4
 T-cells (6  10
6) were cotransferred with 1  10
7 NOD-Thy1.1 or
NOD-CD45.2 congenic CD4
-depleted spleen and LN cells, all from
4-week-old donor mice, into NOD-SCID mice. After 10 weeks, mice
were infected with Vac-IGRP and IGRP-tetramer
 CD8
 T-cells mea-
sured in the spleen 7 days later. Pooled data from three experiments
are shown; NOD (5.6%, IQR 2.7–13%) vs. Idd9 (1%. IQR 0.7–2.1%) P 
0.027 (*). In the second (circles) and third (squares) experiments the
CD4
 T-cells were puriﬁed by FACS sorting. Horizontal line depicts
median value.
FIG. 8. The frequency of naturally occurring naive and activated
phenotype CD4
 cells differs between NOD and Idd9 mice. Spleens of
female 8- to 10-week-old mice were analyzed for expression of CD4,
CD62L, and CD44 by ﬂow cytometry. A: Representative FACS plots. B:
Frequency of CD4
CD62L
CD44
 naive cells. C: Frequency of
CD4
CD62L
CD44
 activated phenotype cells. Three pooled experi-
ments are shown. Horizontal line depicts mean value. Groups compared
by Student t test. A: NOD (48.5  6.6%) vs. Idd9 (58.4  6.1%), P 
0.0009 (**). NOD vs. Idd9.3 (56.4  8.1%), P  0.02 (*). B: NOD (19.4 
3.3%) vs. Idd9 (15.4  22%), P  0.002 (**), NOD vs. Idd9.2 (16.6 
1.5%), P  0.04 (*) (mean  SD).
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